Current Report Filing (8-k)
August 14 2019 - 5:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): August 14, 2019
REGEN BIOPHARMA, INC.
(Exact name of small business issuer
as specified in its charter)
Nevada
|
45-5192997
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Commission File No. 333-191725
4700 Spring Street, St 304, La Mesa,
California 91942
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On August 14
th
, 2019 5,000,000 common shares
of KCL Therapeutics, Inc. (“KCL”) owned by Dr. Harry Lander were cancelled by KCL pursuant to a request from Dr. Lander
received by KCL on August 13
th
2019.
As a result of this cancellation, as of August 14
th
2019 KCL is wholly owned by Regen Biopharma, Inc.
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
REGEN BIOPHARMA, INC.
|
|
|
Dated: August 14, 2019
|
By:
/s/ David Koos
|
|
David Koos
|
|
Chief Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Sep 2023 to Sep 2024